ERNEST HAWK to Research Design
This is a "connection" page, showing publications ERNEST HAWK has written about Research Design.
Connection Strength
0.458
-
When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design. Cancer Prev Res (Phila). 2016 Feb; 9(2):125-7.
Score: 0.320
-
Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement. Cancer. 2014 Apr 01; 120 Suppl 7:1113-21.
Score: 0.071
-
Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am. 2002 Dec; 31(4):971-99.
Score: 0.032
-
Correspondence re: E. Hawk, et al., Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):415-6.
Score: 0.014
-
Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus. 2003; 16(3):177-86.
Score: 0.008
-
Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2000 Feb; 9(2):127-37.
Score: 0.007
-
Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl. 1996; 25:1-14.
Score: 0.005